Avenue Therapeutics, Inc. Common Stock
ATXI
ATXI was delisted on the 18th of March, 2025.
33 hedge funds and large institutions have $12.2M invested in Avenue Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 6 closing their positions.
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
6% more funds holding
Funds holding: 31 → 33 (+2)
59% less capital invested
Capital invested by funds: $29.7M → $12.2M (-$17.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.37M |
| 2 |
State Street
Boston,
Massachusetts
|
+$147K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$142K |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$131K |
| 5 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$99.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$10.7M |
| 2 |
Renaissance Technologies
New York
|
-$822K |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$778K |
| 4 |
MAM
Martingale Asset Management
Boston,
Massachusetts
|
-$215K |
| 5 |
Nisa Investment Advisors
St. Louis,
Missouri
|
-$207K |
ATXI Hedge Fund Activity: Q4 2020 in Review
33 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q4 2020, worth a combined $12.2M — down 59% from $29.7M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ATXI positions and 6 closed out — a net gain of 2 holders — while 11 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.37M. The largest seller was Opaleye Management, exiting entirely with an estimated $10.7M sold.
- 33 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q4 2020, up from 31 in Q3 2020.
- Funds reported $12.2M of Avenue Therapeutics, Inc. Common Stock stock for Q4 2020, down 59% quarter-over-quarter.
- 8 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q4 2020 and 6 closed out, a net change of +2 holders.
- The largest Avenue Therapeutics, Inc. Common Stock buyer in Q4 2020 was Vanguard Group, an estimated $1.37M added.
- The largest Avenue Therapeutics, Inc. Common Stock seller in Q4 2020 was Opaleye Management, an estimated $10.7M sold.
Based on aggregated 13F filings for Q4 2020.